Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari fo... Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. Mehr anzeigen
− Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months − − At These Doses, Peak Reduction of Mean TTR...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global...
− Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business – −...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present data from its transthyretin amyloidosis (ATTR) and hypertension...
− Antrag auf Variation des Typs II auf der Grundlage der positiven Phase-3-Studie HELIOS-B, in der Vutrisiran das Risiko von Todesfällen und kardiovaskulären Ereignissen im Vergleich zu Placebo...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on...
− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – Alnylam...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -13.39 | -5.10717827447 | 262.18 | 262.825 | 229.855 | 1172095 | 239.36249414 | CS |
| 4 | -45.13 | -15.3545182363 | 293.92 | 301.045 | 229.855 | 976056 | 264.4936806 | CS |
| 12 | -30.62 | -10.9588060556 | 279.41 | 304.39 | 229.855 | 869382 | 270.11183851 | CS |
| 26 | 99.35 | 66.4815310493 | 149.44 | 304.39 | 146.79 | 972959 | 246.18286343 | CS |
| 52 | 83.87 | 50.8549599806 | 164.92 | 304.39 | 141.975 | 838147 | 211.62607551 | CS |
| 156 | 61.97 | 33.1709667059 | 186.82 | 304.39 | 117.58 | 810913 | 193.74551852 | CS |
| 260 | 141.79 | 132.514018692 | 107 | 304.39 | 84.97 | 742789 | 176.81485205 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
